[HTML] sciencedirect.com

[HTML][HTML] Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous NSCLC harboring EGFR mutations …

H Kenmotsu, K Wakuda, K Mori, T Kato… - Journal of thoracic …, 2022 - Elsevier
Introduction To evaluate the efficacy and safety of osimertinib plus bevacizumab for
previously untreated patients with advanced nonsquamous NSCLC harboring EGFR …
被引用次数：63 相关文章 所有 5 个版本
[PDF] jto.org

LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

S Ramalingam, JCH Yang, CK Lee, T Kurata… - Journal of Thoracic …, 2016 - jto.org
Background Osimertinib (AZD9291) is a potent, irreversible EGFR-TKI selective for EGFR-
TKI-sensitising (EGFRm) and T790M resistance mutations. We present updated efficacy and …
被引用次数：94 相关文章 所有 5 个版本
[HTML] sciencedirect.com

[HTML][HTML] A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed …

RA Soo, JY Han, U Dafni, BC Cho, CM Yeo, E Nadal… - Annals of …, 2022 - Elsevier
Background While osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small …
被引用次数：62 相关文章 所有 9 个版本

First-line osimertinib for previously untreated patients with NSCLC and uncommon EGFR mutations: the UNICORN phase 2 nonrandomized clinical trial

Y Okuma, K Kubota, M Shimokawa, K Hashimoto… - JAMA …, 2024 - jamanetwork.com
Importance Non–small cell lung cancer (NSCLC) with uncommonEGFRmutations is a rare
subgroup, composing 14% of allEGFRmutations. Objective To determine the usefulness of …
被引用次数：11 相关文章 所有 3 个版本
[HTML] sciencedirect.com

[HTML][HTML] Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M–positive NSCLC following previous EGFR TKI therapy: CAURAL brief report

JCH Yang, FA Shepherd, DW Kim, GW Lee… - Journal of Thoracic …, 2019 - Elsevier
Introduction Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor (TKI).
Durvalumab is an anti–programmed death ligand 1 monoclonal antibody. The phase III …
被引用次数：182 相关文章 所有 10 个版本
[HTML] sciencedirect.com

[HTML][HTML] Osimertinib plus durvalumab in patients with EGFR-mutated, advanced NSCLC: A phase 1b, open-label, multicenter trial

MJ Ahn, BC Cho, X Ou, A Walding, AW Dymond… - Journal of Thoracic …, 2022 - Elsevier
Introduction EGFR tyrosine kinase inhibitors (TKIs) are recommended for EGFR-mutated
NSCLC treatment. EGFR activation up-regulates programmed death-ligand 1 expression …
被引用次数：39 相关文章 所有 7 个版本
[HTML] nih.gov

Combining osimertinib with chemotherapy in EGFR-mutant NSCLC at progression

MN White, Z Piotrowska, K Stirling, SV Liu… - Clinical lung cancer, 2021 - Elsevier
Background Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that has
improved survival and central nervous system (CNS) outcomes in patients with non–small …
被引用次数：29 相关文章 所有 8 个版本
[HTML] sciencedirect.com

[HTML][HTML] Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment …

K Tanaka, H Asahina, J Kishimoto, Y Miyata… - European Journal of …, 2021 - Elsevier
Background Osimertinib is now a standard treatment for patients with previously untreated
EGFR-mutated advanced non–small cell lung cancer (NSCLC). We here investigated …
被引用次数：36 相关文章 所有 6 个版本
[PDF] psu.ac.th

Postprogression outcomes for osimertinib versus standard-of-care egfr-tki in patients with previously untreated egfr-mutated advanced non–small cell lung cancer

D Planchard, MJ Boyer, JS Lee, A Dechaphunkul… - Clinical Cancer …, 2019 - AACR
Purpose: In the phase III FLAURA study, third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free …
被引用次数：70 相关文章 所有 6 个版本
[HTML] sciencedirect.com

[HTML][HTML] Osimertinib versus standard of care EGFR TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset

BC Cho, B Chewaskulyong, KH Lee… - Journal of Thoracic …, 2019 - Elsevier
Introduction Here we report efficacy and safety data of an Asian subset of the phase III
FLAURA trial (NCT02296125), which compares osimertinib with standard of care (SoC) …
被引用次数：113 相关文章 所有 13 个版本